Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of Non-Hodgkin's Lymphoma of the mantle cell sub-type lymphoma only, as determined by morphologic assessment and consistent immunophemotypic markers~* Newly diagnosed and patients who have received prior treatment are eligible~* Measurable or evaluable disease~* Karnofsky performance status greater or equal to 50%~* Men and women, age greater or equal to 18 years old~* AGC greater or equal to 1.0; platelets greater or equal to 75,000; Hemoglobin greater or equal to 8.0 (unless because of lymphomatous infiltration of the marrow)~* Creatinine less than 2.0; bilirubin less than 2.0; SGOT less than 3 times upper limit of normal (unless elevations are due to lymphomatous involvement)~* Women of child bearing potential must have negative pregnancy test within 14 days of study entry.~* Signed informed consent~Exclusion Criteria:~* History of congestive heart failure or significant cardiac disease~* Prior exposure to either fludarabine or mitoxantrone. Prior exposure to rituximab allowed~* Active infection~* HIV seropositive~* Pregnant or lactating females~* Second active malignancy, other than squamous cell skin cancer,in-situ cervical cancer, or history of other cancer diagnosed within the preceding 5 years~* Presence of psychological or emotional disorders which would make valid informed consent impossible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).